NCT06625775: Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics). Phase: PHASE1. Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer